Block Listing Return

RNS Number : 1158D

MaxCyte, Inc.

01 March 2022

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Block Listing Return

Gaithersburg, Maryland - 1 March 2022:  MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading provider of enabling platform technologies for ex-vivo cell engineering, makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

Name of applicant:		MaxCyte, Inc.
Name of scheme:		MaxCyte Long Term Incentive Plan
Period of return:	From:	1 September 2021	To:	28 February 2022
Balance of unallotted securities under scheme(s) from previous return:		78,658 ordinary shares of common stock of $0.01 each
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		13,000,000 ordinary shares of common stock of $0.01 each
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		901,574ordinary shares of common stock of $0.01 each

Name of contact:	Amanda Murphy, Chief Financial Officer Ron Holtz, Chief Accounting Officer
Telephone number of contact:	[phone]

	For further information, please contact: MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA	[phone] [e-mail]
	Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
	UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation®platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

 

END

 

 

BLRFFFVLFFITFIF